Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

COVID-19 Outpatient Thrombosis Prevention Trial ACTIV-4:A multicenter adaptive randomized placebo-controlled platform trial evaluating efficacy and safety of antithrombotic strategies in COVID-19 adults not requiring hospitalization at diagnosis (ACTIV4B)

ABSTRACT: COVID-19 Outpatient Thrombosis Prevention Trial ACTIV-4:A multicenter adaptive randomized placebo-controlled platform trial evaluating efficacy and safety of antithrombotic strategies in COVID-19 adults not requiring hospitalization at diagnosis (ACTIV4B)

PROVIDER: PRJNA783110 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

Project description:ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

| PRJNA1227597 | ENA

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

Project description:ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

| PRJNA1227596 | ENA

COVID-19 Outpatient Thrombosis Prevention Trial ACTIV-4:A multicenter adaptive randomized placebo-controlled platform trial evaluating efficacy and safety of antithrombotic strategies in COVID-19 adults not requiring hospitalization at diagnosis (ACTIV4B)

Project description:COVID-19 Outpatient Thrombosis Prevention Trial ACTIV-4:A multicenter adaptive randomized placebo-controlled platform trial evaluating efficacy and safety of antithrombotic strategies in COVID-19 adults not requiring hospitalization at diagnosis (ACTIV4B)

| PRJNA783111 | ENA

Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19)

Project description:To understand and analyse the global impact of COVID-19 on outpatient services, inpatient care, elective surgery, and perioperative colorectal cancer care, a DElayed COloRectal cancer surgery (DECOR-19) survey was conducted in collaboration with numerous international colorectal societies with the objective of obtaining several learning points from the impact of the COVID-19 outbreak on our colorectal cancer patients which will assist us in the ongoing management of our colorectal cancer patients and to provide us safe oncological pathways for future outbreaks.

| 2346925 | ecrin-mdr-crc

COVID-19: Post-hospital Thromboprophylaxis A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (ACTIV-4C)

Project description:COVID-19: Post-hospital Thromboprophylaxis A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge (ACTIV-4C)

| PRJNA881453 | ENA

| PRJNA881454 | ENA

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

Project description:Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However, quantifiable risk-factors for PASC and their biological associations are poorly resolved. We executed a deep multi-omic, longitudinal investigation of 309 COVID-19 patients from initial diagnosis to convalescence (2-3 months later), integrated with clinical data, and patient-reported symptoms. We resolved four PASC-anticipating risk factors at the time of initial COVID-19 diagnosis: type 2 diabetes, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, and specific autoantibodies. In patients with gastrointestinal PASC, SARS-CoV-2-specific and CMV-specific CD8+ T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent chronic conditions and suggests PASC treatment strategies.

2022-02-01 | E-MTAB-10129 | biostudies-arrayexpress

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [long-read RNA-Seq]

Project description:A subset of individualsenrolledina randomised controlled trial ofChAdOx1 nCoV-19 and received either ChAdOx1 COVID-19 or control MenACWY vaccine whoexperienced COVID-19-associated symptoms were evaluated using multi-omictechnologies. Participants were selected to represent symptomatic individuals with and without COVID-19 as determined by a nucleic acid amplification test (NAAT).

2024-03-04 | GSE228840 | GEO

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [Illumina RNA-Seq]

2024-03-04 | GSE228839 | GEO

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [small RNA-Seq]

2024-03-04 | GSE228841 | GEO